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Antineutrophil cytoplasmic autoantibody (ANCA)-associated
pauci-immune glomerulonephritis (GN) is the most common
finding in very elderly patients biopsied for acute kidney
injury. Appropriate treatment strategies in this age group are
currently undefined since it is unclear whether the benefits
of immunosuppression exceed the risks. We retrospectively
evaluated a cohort of 78 cases of biopsy-proven
pauci-immune GN in individuals aged >80 years of whom
72% were p-ANCA and 20% were c-ANCA positive. The
patients treated with immunosuppression had a significantly
lower incidence of end-stage renal disease (ESRD) 1 year after
biopsy (36%) compared with untreated patients (73%;
P¼ 0.03). Only peak serum creatinine before biopsy and the
use of immunosuppression influenced progression to ESRD.
There was no significant difference in the 1-year mortality
rates between these groups (46 vs 64%; P¼ 0.3). However,
when follow-up was extended beyond 2 years,
immunosuppression was associated with a lower risk of
death (HR 0.33, 95% CI 0.11–0.97) and death or ESRD
(HR 0.16, 95% CI 0.06–0.42) in multivariable models.
Kidney International (2011) 79, 757–764; doi:10.1038/ki.2010.489;
published online 15 December 2010
KEYWORDS: ANCA; elderly; glomerulonephritis; vasculitis
The elderly population in the United States is growing, and as
life expectancy increases, more elderly patients are surviving
longer with acute and chronic diseases. We recently reported
the largest series of renal biopsy findings in the very elderly,
defined as patients X80 years of age.1 In this group, pauci-
immune glomerulonephritis (GN) was the most frequent
diagnosis, occurring in 19% of biopsied patients. Moreover,
among very elderly patients presenting with acute kidney
injury, the frequency of pauci-immune GN rose to 33% of
biopsied patients, and among those with available data,
antineutrophil cytoplasmic autoantibody (ANCA) seroposi-
tivity was documented in 31 of 32 patients.1
Despite improved therapies, ANCA-associated pauci-
immune GN is associated with an approximately 20%
mortality rate within the first year of diagnosis and results
in end-stage renal disease (ESRD) in up to 25% of surviving
patients within the first 4 years after diagnosis.2–6 These
outcome data are drawn from patients of all ages with
ANCA-associated pauci-immune GN. Previous reports
examining the course of ANCA-associated pauci-immune
GN in the elderly, generally defined as465 years of age, have
demonstrated a poorer prognosis for older patients, with
significantly higher rates of death, ESRD, and treatment-
related complications than their younger counterparts.7–9
Very elderly patients (aged X80 years) would be anticipated
to experience even worse outcomes, given their advanced age
and greater prevalence of comorbidities.
We therefore performed the first investigation into the
clinical course of very elderly patients with ANCA-associated
pauci-immune GN. In a retrospective cohort analysis, we
describe overall rates of morbidity and mortality and
examine whether clinical or histopathologic parameters at
the time of biopsy diagnosis, including the decision to treat
with immunosuppressive therapy, predict outcomes of ESRD
or death.
RESULTS
Seventy-eight patients who were X80 years of age and had
renal biopsy findings of pauci-immune GN were identified
(Figure 1). The mean age of the cohort was 83.3 years; 74.4%
of the subjects were female and 90% were Caucasian
(Table 1). The mean creatinine at the time of biopsy was
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4.3mg/dl, and most patients had an active urine sediment
with subnephrotic proteinuria. ANCA serologies were
positive in 93% of subjects, including MPO/p-ANCA in
72%, PR3/c-ANCA in 20%, and both p- and c-ANCA in
1.4%. Thirty-four patients (44%) had extra renal manifesta-
tions of vasculitis, including 34% with pulmonary involve-
ment. Pre-existent conditions included diabetes mellitus
(19%), hypertension (78%), congestive heart failure/coron-
ary artery disease (25%), and malignancy (15%).
Follow-up data were available for 69 of 78 patients.
Duration of follow-up ranged from 1 week to 67 months, as
patients were followed until death or their last clinical
encounter. Median follow-up time for all subjects was 9
months. Thirty-seven of 69 (54%) patients expired within 1
year of biopsy diagnosis.
Among the 61 individuals for whom detailed treatment
decisions by their nephrologists were available, 11 did not
receive immunosuppressive therapy (Table 2). These 11
patients had similar age, creatinine, and comorbidity status
as the 50 patients who did receive immunosuppressive
treatment. Only 1 of 11 untreated patients had extra renal
manifestations of vasculitis, whereas more than half of the
treated patients had extra renal disease (P¼ 0.004 for
comparison). Furthermore, although the difference was not
statistically significant, patients treated with immunosup-
pression were more likely to have an active urinary sediment
than untreated patients. On biopsy, this translated to
approximately twice the percentage of glomeruli with active
necrosis and/or cellular crescents in the treated versus
untreated patients (P¼ 0.02).
The most commonly used induction phase therapy was a
combination of steroids and cyclophosphamide (usually
given orally; Table 3). Three patients additionally received a
short course of plasma exchange (3 to 5 treatments) at the
beginning of induction therapy. At the end of the induction
phase of therapy, 33 of 50 patients treated with immuno-
suppression were alive, including 7 who were dialysis
dependent. Among the remaining 26 who were not dialysis
dependent, 17 (65%) received maintenance phase therapy,
which most commonly consisted of steroids alone (n¼ 4) or
with oral cyclophosphamide (n¼ 4). Among the seven
patients who were dialysis dependent at 6 months, 3 received
maintenance therapy and none recovered renal function.
Among the 20 subjects who received maintenance therapy,
the median duration of treatment was 6 months.
Infections were predictably higher in the immunosup-
pressed group (38 vs 9%; P¼ 0.06) and were predominantly
community- and hospital-acquired pneumonias (that is,
non-pneumocystis pneumonias). During the period of
evaluation, only one patient was diagnosed with a new
malignancy. This patient received immunosuppression with
steroids and intravenous cyclophosphamide followed by
azathioprine maintenance therapy, and was diagnosed with
a melanoma metastatic to the lungs at 12 months following
the initial diagnosis of pauci-immune GN. Relapse rates were
low in both those patients treated (2 of 47) and not treated
(0 of 11) with immunosuppression; in this cohort, both
relapses presented as recurrent bouts of renal failure and
occurred during tapering of maintenance immunosuppression.
Patients treated with immunosuppressive therapy of any
duration had a significantly lower incidence of ESRD within
the first year after biopsy than non-treated patients (36 vs
73%; P¼ 0.03). This lower ESRD rate did not translate to a
statistically significant lower 1-year mortality rate, as 47% of
14,152 Native renal biopsies read at CUMC from 2001–2008
83 Patients  80 years with pauci-immune GN
78 Patients  80 years with pauci-immune GN
5 with anti-GBM
disease
61 Patients with full data on treatment
decisions and overall outcomes
9 with no follow-up
available
8 with limited
follow-up data
50 Patients treated with
immunosuppression
11 Patients not treated 
with immunosuppression
Figure 1 | Study flow diagram. Eighty-three patients with pauci-immune glomerulonephritis (GN) aged 80 years and above were identified,
of whom 5 were excluded due to concomitant antiglomerular basement membrane disease. Of the remaining 78, 9 had no follow-up data
and 8 had only limited follow-up data available, leaving 61 patients with full follow-up data (50 treated with immunosuppression, 11
untreated). CUMC, Columbia University Medical Center.
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treated patients died within 1 year compared with 64% of
untreated patients (P¼ 0.3). When the follow-up period was
extended past 1 year, however, in multivariate Cox proportional
hazards models, receipt of any immunosuppressive therapy was
associated with a significantly lower risk for ESRD (hazard ratio
0.17, 95% confidence interval (CI) 0.05–0.52, P¼ 0.002), death
(hazard ratio 0.33, 95% CI 0.11–0.97, P¼ 0.04), and the
combined outcome of death or ESRD (hazard ratio 0.16, 95%
CI 0.06–0.42, Po0.001; Figures 2–4). The mean and median
creatinine in those surviving and not on dialysis at the end of
the study was 1.6mg/dl.
We used logistic regression to explore predictors of the
outcomes of ESRD and death at 1 year in this cohort
(Table 4). In multivariate analysis, only peak serum
creatinine before biopsy and use of immunosuppressive
therapy influenced progression to ESRD. In multivariate
analysis, no histological parameter predicted progression to
ESRD, although 450% open glomeruli, which predicted a
reduced odds of ESRD in univariate analysis, could not be
tested in multivariate models due to significant correlation
with serum creatinine. In multivariate analysis, no clinical or
histological parameter predicted death at 1 year, although
immunosuppression demonstrated a clear, nonsignificant
trend towards reduced odds of death. The receiver-operating
characteristic curve for those subjects who received immu-
nosuppression suggested that therapy exerted its greatest
benefit in reducing the risk for ESRD or death in those
subjects whose peak creatinine was 4.5mg/dl or lower at the
time of diagnosis (Figure 5). Receiver-operating characteristic
curves for the entire cohort and the subcohort who received
immunosuppression showed similar areas under the curve of
0.73 (95% CI 0.61–0.85) and 0.77 (95% CI 0.64–0.91),
respectively.
DISCUSSION
In this retrospective cohort study, we describe the clinical
course of ANCA-associated pauci-immune GN in the very
elderly, defined as patients at least 80 years of age at the time
of diagnosis. As a whole, this group had a high rate of
morbidity and mortality, with nearly 70% of patients
reaching a combined end point of ESRD or death within
the first year of diagnosis. The use of immunosuppressive
therapy for this population, therefore, must be considered in
the context of this significant morbidity and mortality.
Within our cohort, immunosuppressive therapy significantly
reduced the risk of ESRD and the combined outcome of
ESRD or death within the first year after diagnosis, but an
overall mortality benefit was not demonstrated in this time
period. However, over longer periods of follow-up, immu-
nosuppressive therapy did demonstrate a sustained and
significant reduction in the risk of death that paralleled
reductions in the risk of ESRD and the combined outcome of
ESRD or death.
Previous reports have examined ANCA-associated vascu-
litis in elderly populations, yet these patients have generally
been younger than those in our cohort and did not
universally have renal involvement. Kaplan-Pavlovcic et al.8
followed 37 patientsX60 years with ANCA-associated pauci-
immune GN and reported that 16% progressed to ESRD
within 3 years of diagnosis. Chen et al.9 compared 99 patients
with ANCA vasculitis X65 years of age (mean 72.1 years)
with 135 younger patients (mean 49.3 years). Older patients
were less likely to respond to immunosuppressive therapy
and had worse overall survival. In multivariate analyses, each
10-year increase in age was associated with a 50% increased
risk for death.9 Harper and Savage7 used this same age
dichotomy (465 vs p65 years) to compare their older and
younger patients with ANCA vasculitis. The older patients
(mean age 70 years) showed similar response rates to therapy
as their younger patients (mean age 50.5 years), but had
Table 1 | Characteristics of study participants (N=78)
Age 83.3±2.7
Female 58/78 (74.4%)
Race
Caucasian 66/73 (90.4%)
African American 3/73 (4.1%)
Hispanic 4/73 (5.5%)
Peak serum creatinine pre-biopsy, mg/dl 4.3±2.5
Proteinuria, mg/day 1723.7±1975.6
Dipstick proteinuriaa
Negative 1/12 (8.3%)
1+ 3/12 (25.0%)
2+ 4/12 (33.3%)
3+ 4/12 (33.3%)
Active urine sediment 50/65 (76.9%)
ANCA typeb
Negative 5/71 (7.0%)
MPO/p-ANCA 51/71 (71.8%)
PR3/c-ANCA 14/71 (19.7%)
p- and c-ANCA 1/71 (1.4%)
Extra renal manifestations
Lungs 27/78 (34.6%)
Skin 3/78 (3.8%)
ENT 4/78 (5.1%)
GI 3/78 (3.8%)
Pre-existent diabetes 13/69 (18.8%)
Pre-existent hypertension 54/69 (78.3%)
Comorbid conditions
None 24/72 (33.3%)
CHF/CAD 18/72 (25.0%)
Cancer 11/72 (15.3%)
CKD 5/72 (6.9%)
COPD/interstitial lung disease 10/72 (13.9%)
Cerebrovascular disease 6/72 (8.3%)
RA/PMR/temporal arteritis 7/72 (9.7%)
Abbreviations: ANCA, antineutrophil cytoplasmic autoantibody; CAD, coronary
artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD,
chronic obstructive pulmonary disease; ENT, ear-nose-throat; GBM, glomerular
basement membrane; GI, gastrointestinal; PMR, polymyalgia rheumatica; RA,
rheumatoid arthritis.
Values are either mean±s.d. or N (%) and exclude missing data.
aDipstick proteinuria only reported for those subjects without proteinuria quantified
by either 24 h collection or random urine protein:creatinine ratio.
bExcludes seven patients for whom ANCA serology testing was not performed or
reported.
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significantly worse overall survival with death typically
occurring early (median time to death of 3 months).7
Hoganson et al.,10 comparing 22 patients with ANCA
vasculitis over 75 years of age with 56 patients under 75
years, reported a significantly higher mortality risk (40 vs
11% over 3 years of follow-up), but o25% of their patients
had renal involvement. Again, death occurred early—more
than half of the deaths transpired within 6 months of
diagnosis.10
Our data show a similar message of high morbidity and
mortality, particularly within the first 6 months after
diagnosis. The survival curves for the outcomes of ESRD,
death, and the combined outcome of ESRD or death in this
cohort (Figures 2–4) are particularly informative, suggesting
that the benefit of immunosuppressive therapy is experienced
early (that is, within the first 6 months) in the form of
reduced risk for ESRD and later (that is, after 1 year) in the
form of prolonged survival and, in particular, prolonged
dialysis-free survival. We note that, in post hoc power
analyses, we were only sufficiently powered (X80%) to
detect a 75% lower incidence of death within the first year of
diagnosis; therefore, in a larger sample, early mortality
benefits may be seen more clearly. Receiver-operating
characteristic curve analysis suggested that dialysis-free
survival could be expected most often in patients who
present with a creatinine of 4.5mg/dl or lower. Our cohort
demonstrated low rates of relapse (4%) but high rates of
infection (38%) in treated patients, a clinical course that has
been demonstrated by ANCA-associated pauci-immune GN
patients on chronic dialysis of all ages.11 Indeed, the
reduction in morbidity and mortality associated with
immunosuppression persisted, despite this higher infection
rate, suggesting again that the substantial risk of therapeutic
complications is outweighed by the potential treatment
benefits for select patients.
This study is, to our knowledge, the first to examine the
clinical course of ANCA-associated pauci-immune GN in the
very elderly, defined as patients aged X80 years. Our recent
Table 2 | Clinical and histopathological parameters of patients at the time of biopsy diagnosis, stratified by treatment decision
Treated with
immunosuppressive
therapy (N=50)
Not treated with
immunosuppressive
therapy (N=11) P-value
Clinical parameters
Age, years 83.3±2.7 83.5±3.5 0.9
Female 37/50 (74.0%) 9/11 (81.8%) 0.6
Peak serum creatinine, mg/dl 4.5±2.9 3.9±1.5 0.8
Proteinuria, mg/day 1454±1372 3365±4297 0.2
Active urine sediment 34/43 (79.1%) 4/8 (50.0%) 0.09
ANCA type 0.3a
Negative 4/47 (8.5%) 0/9 (0.0%)
MPO/p-ANCA 32/47 (68.1%) 8/9 (88.9%)
PR3/c-ANCA 10/47 (21.3%) 1/9 (11.1%)
p- and c-ANCA 1/47 (2.1%) 0/9 (0.0%)
Extra renal manifestations 28/50 (56.0%) 1/11 (9.1%) 0.004
Pre-existent diabetes 9/48 (18.8%) 3/10 (30.0%) 0.4
Pre-existent hypertension 41/49 (83.7%) 8/10 (80.0%) 0.8
Significant comorbidities 34/47 (72.3%) 6/10 (60.0%) 0.4
Histopathological parameters
Number of glomeruli on LM 17.1±8.0 16.8±8.5 0.9
% Globally sclerotic glomeruli 28.2±17.6 39.1±25.6 0.2
% Glomeruli with fibrinoid necrosis and/or cellular crescents 26.2±20.2 12.8±14.7 0.02
% Glomeruli with segmental sclerosis and/or fibrocellular crescent 10.1±13.6 16.3±24.8 0.6
% Open glomeruli 35.0±21.5 24.5±22.3 0.1
% Tubular atrophy and/or interstitial fibrosis 29.3±19.4 36.8±30.4 0.7
Interstitial inflammation
Absent 0/50 (0.0%) 0/11 (0.0%) 0.3a
Mild 25/50 (50.0%) 7/11 (63.6%)
Moderate 17/50 (34.0%) 4/11 (36.4%)
Severe 8/50 (16.0%) 0/11 (0.0%)
Vascular disease 0.7a
Absent 3/50 (6.0%) 1/10 (10.0%)
Mild 16/50 (32.0%) 1/10 (10.0%)
Moderate 24/50 (48.0%) 7/10 (70.0%)
Severe 7/50 (14.0%) 1/10 (10.0%)
Abbreviations: ANCA, antineutrophil cytoplasmic autoantibody; LM, light microscopy.
Values are either mean±s.d. or N (%) and exclude missing data.
aP-value for trend across categories.
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report on renal biopsy findings in this age group showed that
pauci-immune GN was the most frequent reported diagnosis,
occurring in 19% of all biopsied patients and 33% of patients
biopsied for acute kidney injury. Furthermore, compared
with middle-aged patients undergoing kidney biopsy, pauci-
immune GN was diagnosed 2.5 times more frequently in the
very elderly.1 Therefore, this is a commonly encountered
clinical entity for which treatment decisions are not intuitive,
given the advanced age and often heavily comorbid status of
such patients. The results from our cohort, which is of
considerable size, provide guidance for clinicians and their
patients.
However, there are limitations to this study. First, this is a
retrospective analysis that is reliant only upon data made
Table 3 | Clinical course of subjects after biopsy diagnosis
Treated with
immunosuppressive
therapy (N=50)
Not treated with
immunosuppressive
therapy (N=11) P-value
Induction therapy
Steroids alone 6/50 (12.0%) NA
Steroids+PO CTX 29/50 (58.0%) NA NA
Steroids+IV CTX 12/50 (24.0%) NA
MMF 3/50 (6.0%) NA
Maintenance therapya
None 9/26 (34.6%) NA NA
Steroids alone 4/26 (15.4%) NA
Steroids+PO CTX 4/26 (15.4%) NA
Steroids+MMF 1/26 (3.8%) NA
Steroids+AZA 2/26 (7.7%) NA
MMF alone 3/26 (11.5%) NA
AZA alone 3/26 (11.5%) NA
Duration of immunosuppressive therapy,
months (median, range)b
6 (1–67) NA NA
ESRD within 1 year 17/47 (36.2%) 8/11 (72.7%) 0.03
Death within 1 year 23/49 (46.9%) 7/11 (63.6%) 0.3
Death or ESRD within 1 year 27/48 (56.2%) 10/11 (90.9%) 0.03
Remissionc 23/47 (48.9%) 0/11 (0.0%) 0.002
Relapsec 2/47 (4.3%) 0/11 (0.0%) 0.5
Infection 18/47 (38.3%) 1/11 (9.1%) 0.06
Abbreviations: AZA, azathioprine; CTX, cyclophosphamide; ESRD, end-stage renal disease; IV, intravenous; MMF, mycophenolate mofetil; NA, not applicable; PO, oral.
aData represent those patients alive and not dialysis dependent after 6 months of induction phase therapy.
bFollow-up data available for 47 of 50 subjects; duration reflects both induction and, when administered, maintenance phase of therapy.
cDisease remission was defined as resolution of renal failure with no symptoms of extra renal vasculitis; disease relapse was defined as recurrent bouts of renal failure and/or
extra renal manifestations of vasculitis.
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Figure 2 |Kaplan–Meier survival curves for the outcome of
end-stage renal disease (ESRD). Curves reflect univariate
analyses. In multivariate Cox proportional hazards model, the use
of immunosuppressive therapy significantly reduced the risk of
ESRD over the duration of follow-up (hazard ratio 0.17, confidence
interval 0.05–0.52, P¼ 0.002).
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Figure 3 |Kaplan–Meier survival curves for the outcome of
death. Curves reflect univariate analyses. In multivariate Cox
proportional hazards model, the use of immunosuppressive
therapy significantly reduced the risk of death over the duration
of follow-up (hazard ratio 0.33, confidence interval 0.11–0.97,
P¼ 0.04).
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Figure 4 |Kaplan–Meier survival curves for the combined
outcome of end-stage renal disease (ESRD) or death. Curves
reflect univariate analyses. In multivariate Cox proportional
hazards model, the use of immunosuppressive therapy
significantly reduced the risk of death or ESRD over the duration
of follow-up (hazard ratio 0.16, confidence interval 0.06–0.42,
Po0.001).
Table 4 | Association between key clinical or histological parameters and outcomes of ESRD and death within 1 year of biopsy
Univariate analysis Multivariate analysisa
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
ESRD
Age 1.10 (0.91–1.33) 0.3 1.02 (0.99–1.04)a 0.2
Female gender 0.69 (0.21–2.32) 0.6 0.77 (0.15–3.90) 0.8
White race 1.31 (0.28–6.09) 0.7 1.37 (0.12–15.17) 0.8
Peak creatinine 1.22 (0.94–1.58) 0.1 1.26 (1.02–1.83) 0.04
pANCA 0.55 (0.19–1.64) 0.3 0.45 (0.10–1.92) 0.3
DM 0.75 (0.19–2.95) 0.7 0.47 (0.07–3.27) 0.3
HTN 1.96 (0.45–8.54) 0.4 1.02 (0.99–1.04)a 0.2
Other comorbidities 1.09 (0.34–3.49) 0.9 3.40 (0.64–18.06) 0.2
Extra renal manifestations 0.27 (0.09–0.81) 0.02 —b
425% Glomeruli with cellular crescents 0.53 (0.17–1.61) 0.3 0.48 (0.08–2.74) 0.4
430% Tubular atrophy/interstitial fibrosis 1.38 (0.48–3.97) 0.6 1.67 (0.36–7.69) 0.5
450% Open glomeruli 0.20 (0.04–1.02) 0.05 —b
Immunosuppressive therapy 0.21 (0.05–0.91) 0.04 0.13 (0.02–0.78) 0.03
Death
Age 1.27 (1.03–1.55) 0.02 1.01 (0.99–1.03)a 0.3
Female gender 0.55 (0.18–1.69) 0.3 0.49 (0.11–2.24) 0.4
White race 1.90 (0.49–7.46) 0.4 6.48 (0.50–83.74) 0.2
Peak creatinine 1.09 (0.89–1.33) 0.4 1.11 (0.88–1.39) 0.4
pANCA 0.39 (0.14–1.10) 0.08 0.32 (0.08–1.36) 0.1
DM 0.59 (0.16–2.10) 0.4 1.06 (0.22–5.16) 0.9
HTN 1.22 (0.35–4.29) 0.8 1.01 (0.99–1.03)a 0.3
Other comorbidities 0.96 (0.34–2.69) 0.9 1.31 (0.31–5.51) 0.7
Extra renal manifestations 0.86 (0.33–2.24) 0.8 —b
425% Glomeruli with cellular crescents 1.50 (0.55–4.06) 0.4 2.74 (0.61–12.22) 0.2
430% Tubular atrophy/interstitial fibrosis 0.70 (0.26–1.84) 0.5 1.14 (0.30–4.27) 0.8
450% Open glomeruli 0.99 (0.31–3.10) 1.0 —b
Immunosuppressive therapy 0.51 (0.13–1.95) 0.3 0.20 (0.03–1.16) 0.07
Abbreviations: ANCA, antineutrophil cytoplasmic autoantibody; CI, confidence interval; DM, diabetes mellitus; ESRD, end-stage renal disease; HTN, hypertension.
aAge and HTN were entered together, as an interaction variable, in multivariate models due to effect measure modification. The odds ratio therefore represents the change in
odds of outcome for a 1-year increase in age in the presence of hypertension.
bExtra renal manifestations, which correlated highly with use of immunosuppressive therapy, and open glomeruli, which correlated highly with serum creatinine, were not
included in multivariate models.
0.00
0.25
0.50
0.75
1.00
Se
ns
itiv
ity
0.00 0.25 0.50 0.75 1.00
1 – Specificity
Area under ROC curve = 0.7726
Serum Cr 4.5 mg/dl
Figure 5 |Receiver-operating characteristic (ROC) curves of
sensitivity plotted against 1specificity in patients who
received immunosuppressive therapy. The Youden index
(sensitivityþ specificity1) identified a peak serum creatinine of
p4.5mg/dl as the level at which immunosuppressive therapy
exerted its greatest benefit in reducing the risk for end-stage renal
disease or death during the follow-up period.
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available to the investigators. However, we were able to
obtain varying degrees of follow-up information on more
than 85% of patients. Next, patients clearly were not
randomized to immunosuppressive therapy, and potential
confounding may exist. We were able to adjust for key clinical
and histological parameters in our analyses, but there may be
factors influencing treatment decisions (for example, pa-
tients’ overall functional status and willingness to pursue
immunosuppressive therapy) that were not quantified and
therefore not entered into our models. Unfortunately, we did
not have data on the dosing of immunosuppression for
treated patients, an important point of consideration for the
very elderly age group. While inadequate doses could explain
some of the failures in this cohort, of greater concern for very
elderly patients is the potential for toxicities with excessive
doses. Our data only support the use of immunosuppression
and not a particular regimen. In addition, our data address
outcomes for ANCA-associated GN and not ANCA-asso-
ciated vasculitis without renal involvement. Therefore, these
results apply only to patients diagnosed with ANCA-
associated disease by kidney biopsy. Finally, the treatment
decisions in our 8-year cohort may not wholly reflect current
treatment decisions, as the last decade has seen a shift away
from oral cyclophosphamide towards intravenous cyclopho-
sphamide for treating vasculitis,12 as well as greater use of
mycophenolate mofetil for both induction and maintenance
therapy13,14 and plasma exchange for patients with severe
renal failure or hemoptysis at presentation.15,16
In conclusion, we present the first report on ANCA-
associated pauci-immune GN in patients X80 years of age.
In this group, the disease is marked by high rates of
morbidity and mortality, with nearly 70% of patients
progressing to ESRD or death within 1 year of diagnosis.
Over long-term follow-up, the use of immunosuppressive
therapy was associated with significantly lower risk of ESRD,
death, and the combined outcome of ESRD or death. The
experience of these patients suggests that immunosuppressive
therapy for very elderly patients with ANCA-associated
pauci-immune GN can prolong dialysis-free survival.
METHODS
Participants and study design
This retrospective cohort study identified all patients aged X80
years, whose native renal biopsies were processed at the Renal
Pathology Laboratory at Columbia University Medical Center
during an 8-year period from January 2001 to December 2008.
During this time, a total of 14,152 native renal biopsies were
analyzed, of which 83 (0.59%) were from patients X80 years who
had a pathological diagnosis of pauci-immune GN (n¼ 78) or
antiglomerular basement membrane disease with co-existent ANCA
seropositivity (n¼ 5). The five patients with ANCA and antiglo-
merular basement membrane positivity were excluded from this
analysis due to lack of a pure ANCA-associated disease. Each
specimen was examined by light microscopy and direct immuno-
fluorescence (for immunoglobulin-G, -M, -A, C3, C1q, fibrinogen,
kappa, and lambda light chains); electron microscopy was
performed on 68 of 78 (87.2%) cases.
For each case, the biopsy report was reviewed by two authors
(ASB, SS) to confirm the pathological diagnosis and to gather
clinical information provided by the referring nephrologist at the
time of biopsy, including medical history, physical examination
findings, and laboratory values. For each case, we attempted to
contact the referring nephrologist to confirm the pre-biopsy data
and obtain follow-up clinical information. We were able to obtain
follow-up data, in varying degrees of completeness, in 69 of 78
(88.5%) cases; full information on treatment decisions and long-
term outcomes were available for 61 of 78 (78.2%) cases. The study
was approved by the Institutional Review Board of Columbia
University Medical Center.
Outcomes
The principal outcomes of interest in this cohort were ESRD, death,
and the combined outcome of ESRD or death. All subjects were
followed until their death or last clinical encounter. ESRD was
defined as initiation of renal replacement therapy; in this cohort,
this end point was entirely hemodialysis. The referring nephrologists
were asked to provide data on whether and when ESRD or death
occurred. We used the social security death index to obtain missing
mortality data and to confirm death information provided by
referring nephrologists. We also examined, when data were available,
secondary outcomes of disease remission (defined as resolution of
renal failure with creatinine returning to no greater than 1.5 times
pre-morbid creatinine level and no symptoms of extra renal
vasculitis), relapse of disease (defined as recurrent bouts of renal
failure and/or extra renal manifestations of vasculitis), infectious
complications, and new malignancies arising after diagnosis.
Clinical predictors of outcomes
We obtained data regarding patients’ pre- and post-biopsy clinical
course in order to examine potential predictors of outcomes. Pre-
biopsy clinical data collected included age, gender, race/ethnicity,
peak serum creatinine, degree of proteinuria (24-h, urine protein:
creatinine ratio, or dipstick values), ANCA serologies, and extra
renal manifestations of vasculitis, including lung, sinus, or skin
involvement. We also obtained data on pre-existent conditions,
including diabetes mellitus, hypertension, and chronic kidney
disease. Post-biopsy clinical data collected included whether or not
immunosuppressive therapy was prescribed, duration of immuno-
suppressive regimens used for induction and/or maintenance, need
for renal replacement therapy, most recent available serum
creatinine, and whether or not the patient had expired.
Statistical analyses
Baseline characteristics for all subjects were presented descriptively,
with mean±s.d. for continuous variables and percentage for
categorical variables. We compared clinical and biopsy parameters
between patients who did and did not receive immunosuppressive
therapy using a two-sample Wilcoxon rank-sum (Mann–Whitney)
test for continuous variables and Fisher’s exact test for categorical
variables. For initial analysis of the outcomes of interest, we used a
two-sample t-test to compare treated and untreated patients.
Incidence odds ratios for ESRD and death within 1 year post-
biopsy were obtained using univariate and multivariate logistic
regression. Logistic regression was used for this analysis to maximize
the number of subjects included, as this analysis allowed inclusion of
subjects whose nephrologists were not able to provide detailed
information on the timing of dialysis initiation. We also used Cox
proportional hazards models to obtain multivariate hazards ratios
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for the outcomes of ESRD, death, and ESRD or death over the entire
duration of follow-up. We had full death data on all analyzed
subjects; for eight subjects identified by their nephrologists as having
reached ESRD but at an unspecified time, we imputed ESRD
initiation time as the midway point between biopsy diagnosis and
death. We constructed univariate Kaplan–Meier survival curves to
complement the hazards models for the outcomes of ESRD, death,
and ESRD or death. In these univariate analyses, the same
imputation of subject time was used as in the hazards models. For
the ESRD analyses, subjects were censored if death occurred before
reaching ESRD.
We evaluated the following predictor variables for our multi-
variate models: age, gender, race, pre-biopsy creatinine, ANCA
serology, pre-existent diabetes or hypertension, pre-existent comor-
bidities, extra renal vasculitis manifestations, 425% of glomeruli
with cellular crescents, 430% tubular atrophy and/or interstitial
fibrosis, 450% open glomeruli, and use of immunosuppressive
therapy. Our binary histopathology variables for crescentic disease
and tubular atrophy/interstitial fibrosis were created by choosing an
easily demarcated cutoff percentage that fell near the mean
percentage of the cohort. We similarly chose 450% open glomeruli
as a cutoff because of its easy demarcation (more than half of the
glomeruli are not affected by disease, akin to the differentiation between
a class III and IV lupus nephritis). Extra renal manifestations, which
correlated highly with use of immunosuppressive therapy, and open
glomeruli, which correlated highly with serum creatinine, were not
included in multivariate models. Likelihood ratio tests that compared
models with and without interaction terms (using a conservative
P-value of 0.15 for such tests of interaction) identified a significant
interaction between pre-existent hypertension and age. Therefore, to
account for this effect measure modification, an interaction term for
age and hypertension was used in multivariate models.
Receiver-operating characteristic curves were constructed using
death or ESRD as the reference variable and peak serum creatinine
as the class variable for the entire cohort and for the subcohort that
received immunosuppression. The Youden index (sensitivityþ
specificity1) was used to determine at which serum creatinine
immunosuppression would exert its greatest effect on ESRD or
death. Analyses and plots were performed using STATA version 9.2
(StataCorp, College Station, TX).
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